Shenzhen Chipscreen Biosciences Co Ltd
SSE:688321
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
13.01
24.93
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Shenzhen Chipscreen Biosciences Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Net Issuance of Debt
Shenzhen Chipscreen Biosciences Co Ltd
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Shenzhen Chipscreen Biosciences Co Ltd
SSE:688321
|
Net Issuance of Debt
¥218.6m
|
CAGR 3-Years
23%
|
CAGR 5-Years
113%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Net Issuance of Debt
-¥19m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Net Issuance of Debt
¥163.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Net Issuance of Debt
-¥16.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Net Issuance of Debt
¥404.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Net Issuance of Debt
¥208m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Shenzhen Chipscreen Biosciences Co Ltd
Glance View
In the bustling city of Shenzhen, often hailed as China's Silicon Valley, Shenzhen Chipscreen Biosciences Co Ltd stands as a testament to innovation in the biopharmaceutical landscape. Founded in 2001, the company embarked on a journey to bridge the gap between cutting-edge bioscience and market needs, focusing on research, development, and commercialization of novel drugs. Chipscreen’s core strength lies in its proprietary chemical genomics-based discovery and development platform, which has carved out a niche in identifying molecular targets and mining drug candidates with high therapeutic potential. The company seamlessly integrates advanced technologies with biotech prowess to design and develop small molecule drugs that address unmet clinical needs, primarily focusing on oncology, autoimmune diseases, and metabolic disorders. The financial engine of Chipscreen Biosciences hums through a well-orchestrated portfolio strategy. By progressing drug candidates through various stages of clinical trials, the company has not only diversified its offerings but also strategically positioned itself in lucrative therapeutic markets. Its revenue model capitalizes on successful product commercialization, primarily through sales of its marketed drugs and royalties from licensing agreements with strategic partners. This collaborative approach enables Chipscreen to maximize its product reach while sharing developmental risks. As the company's innovative therapies gain traction in domestic and global markets, Chipscreen continues its commitment to reinvest in research and development, crafting a sustainable cycle of growth fueled by scientific advancement and strategic acumen.
See Also
What is Shenzhen Chipscreen Biosciences Co Ltd's Net Issuance of Debt?
Net Issuance of Debt
218.6m
CNY
Based on the financial report for Sep 30, 2024, Shenzhen Chipscreen Biosciences Co Ltd's Net Issuance of Debt amounts to 218.6m CNY.
What is Shenzhen Chipscreen Biosciences Co Ltd's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 5Y
113%
Over the last year, the Net Issuance of Debt growth was 17%. The average annual Net Issuance of Debt growth rates for Shenzhen Chipscreen Biosciences Co Ltd have been 23% over the past three years , 113% over the past five years .
You don't have any saved screeners yet
